CLINICAL TRIALS PROFILE FOR INOTUZUMAB OZOGAMICIN
✉ Email this page to a colleague
All Clinical Trials for inotuzumab ozogamicin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00299494 ↗ | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | Completed | UCB Pharma | Phase 1/Phase 2 | 2006-05-04 | The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin [CMC-544] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL. |
| NCT00299494 ↗ | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | Completed | Pfizer | Phase 1/Phase 2 | 2006-05-04 | The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin [CMC-544] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL. |
| NCT00562965 ↗ | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) | Terminated | UCB Pharma | Phase 3 | 2007-11-01 | This protocol is designed to assess the efficacy and safety of inotuzumab ozogamicin given with rituximab compared to a defined investigator's choice therapy. Subjects will be randomized to one of these two arms of the study. |
| NCT00562965 ↗ | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) | Terminated | Pfizer | Phase 3 | 2007-11-01 | This protocol is designed to assess the efficacy and safety of inotuzumab ozogamicin given with rituximab compared to a defined investigator's choice therapy. Subjects will be randomized to one of these two arms of the study. |
| NCT00717925 ↗ | Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL) | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | 2007-03-01 | To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in patients with B-Cell Non-Hodgkin's Lymphoma (NHL). |
| NCT00724971 ↗ | Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab | Completed | Pfizer | Phase 1 | 2008-07-04 | To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in combination with Rituximab in patients with B-Cell Non-Hodgkin's lymphoma (NHL). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for inotuzumab ozogamicin
Condition Name
Clinical Trial Locations for inotuzumab ozogamicin
Trials by Country
Clinical Trial Progress for inotuzumab ozogamicin
Clinical Trial Phase
Clinical Trial Sponsors for inotuzumab ozogamicin
Sponsor Name
